BOSTON, January 13, 2016 /PRNewswire/ --
We are pleased to announce the launch of our new website www.aurigene.com . Our goal with this new website is to provide visitors, our discovery collaboration and out-licensing partners with an easier way to learn about Aurigene.
For our discovery partners, we now have a separate link to take you through the various services and partnering models we offer - the link also provides case studies of "discovery problem-solving" handled by Aurigene scientists - thus demonstrating our track-record in successfully delivering drug candidates to our partners.
For our licensing partners, in addition to the programs available for partnering, we have also introduced brief backgrounds on our scientific strategy and focus areas within oncology and inflammation.
In addition, the new website also contains social media buttons for LinkedIn and Facebook. We will be updating our content with case studies and company announcements from time to time.
We hope you find our revamped website, easy to navigate and access.
Aurigene is a specialized, discovery stage biotechnology company, developing novel and best-in-class therapies to treat cancer and inflammatory diseases. Aurigene's Programmed Death pathway program is the first of several immune checkpoint programs that are at different stages of discovery and preclinical development. Aurigene has signed four licensing deals in the last couple of years. Aurigene is currently seeking partners for its current pipeline of advanced assets (a) RORg for autoimmune diseases which is in preclinical development (b) Novel NAMPT inhibitors for niche cancers, also in preclinical development (c) Covalent CDK7 and KRAS small molecule programs that are currently in lead optimization. For more information about Aurigene and our pipeline, please visit Aurigene's website at http://www.aurigene.com/
Director Corporate Development & Strategy
SOURCE Aurigene Discovery Technologies Limited